Shanghai Henlius Biotech, Inc. (HKG:2696)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
38.95
+1.25 (3.32%)
Apr 24, 2025, 4:08 PM HKT
155.24%
Market Cap 20.49B
Revenue (ttm) 6.09B
Net Income (ttm) 873.12M
Shares Out 543.49M
EPS (ttm) 1.61
PE Ratio 23.47
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 937,600
Average Volume 1,964,143
Open 37.70
Previous Close 37.70
Day's Range 37.10 - 39.00
52-Week Range 15.20 - 39.20
Beta 0.83
RSI 66.65
Earnings Date May 27, 2025

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis; and HANBEITAI, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 3,515
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2696
Full Company Profile

Financial Performance

In 2024, Shanghai Henlius Biotech's revenue was 5.72 billion, an increase of 6.11% compared to the previous year's 5.39 billion. Earnings were 820.47 million, an increase of 50.26%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.